CORRECTION – Dr. Anosh Ahmed Announces Major Expansion of COVID Testing Contracts Across U.S. and International Markets Dr. Anosh Ahmed expands U.S. and international COVID testing contracts with focus on compliance, fraud prevention, and trusted public health services GlobeNewswire July 07, 2025 CHICAGO, July 07, 2025 (GLOBE NEWSWIRE) — In a release issued under the […]
(NasdaqGM:SHLS), PORTLAND, Tenn., July 07, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its second quarter 2025 results before market open on Tuesday, August 5, 2025, to be followed by a conference call at 8:00 a.m. (Eastern Time) on the same day. Interested investors
(Other OTC:OTCM),(OTC US:OTCM),(Other OTC:VRMWW), NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vroom, Inc. (“Vroom”) (OTCQX: VRMWW), a leading automotive finance company and a data and AI-powered analytics and digital services platform supporting the automotive industry,
(Other OTC:MHCUF),(OTC US:MHCUF),(TSX:MHC-U),(TSX:MHC-UN), Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX: MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced that senior management will host a conference call on Thursday, August 7, 2025 at 8:30 a.m. ET
(NasdaqGM:AQST), WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host
Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision in people with diabetic macular edema (DME).1 DME is a leading cause of vision loss in
Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that preclinical data for OMS1620, it's lead program targeting the melanocortin-2 (MC2) receptor, will be presented at ENDO 2025, the Annual Endocrine
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome GlobeNewswire July 07, 2025 Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) — Orchard Therapeutics, a Kyowa Kirin company, today announced the
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema GlobeNewswire July 07, 2025 Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a
Heidmar Maritime Holdings Corp. Acquires Its First Vessel and Establishes Foothold in Container Shipping GlobeNewswire July 07, 2025 ATHENS, Greece and NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — Heidmar Maritime Holdings Corp. (the “Company” or “Heidmar”) (NASDAQ: HMR) today announces its first vessel acquisition, making it a strategic milestone in the Company's project development